2535 related articles for article (PubMed ID: 19095124)
21. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer: epidemiology and health-related quality of life.
Penson DF; Rossignol M; Sartor AO; Scardino PT; Abenhaim LL
Urology; 2008 Dec; 72(6 Suppl):S3-11. PubMed ID: 19095126
[TBL] [Abstract][Full Text] [Related]
23. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
[TBL] [Abstract][Full Text] [Related]
24. Risk stratification in clinically localized prostate cancer.
Aprikian AG
Can J Urol; 2002 Jun; 9 Suppl 1():18-20. PubMed ID: 12121590
[TBL] [Abstract][Full Text] [Related]
25. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007.
Meiers I; Waters DJ; Bostwick DG
Urology; 2007 Dec; 70(6 Suppl):3-8. PubMed ID: 18194709
[TBL] [Abstract][Full Text] [Related]
26. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
Lawrentschuk N; Fleshner N
BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
[TBL] [Abstract][Full Text] [Related]
27. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens.
Epstein JI
J Urol; 2011 Sep; 186(3):790-7. PubMed ID: 21788055
[TBL] [Abstract][Full Text] [Related]
29. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
30. Focal therapy for prostate cancer: pathologic basis.
Mouraviev V; Madden JF
Curr Opin Urol; 2009 Mar; 19(2):161-7. PubMed ID: 19188770
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.
Mouraviev V; Mayes JM; Sun L; Madden JF; Moul JW; Polascik TJ
Cancer; 2007 Aug; 110(4):906-10. PubMed ID: 17587207
[TBL] [Abstract][Full Text] [Related]
32. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Murphy GP; Busch C; Abrahamsson PA; Epstein JI; McNeal JE; Miller GJ; Mostofi FK; Nagle RB; Nordling S; Parkinson C
Scand J Urol Nephrol Suppl; 1994; 162():7-42; discussion 115-27. PubMed ID: 7817162
[TBL] [Abstract][Full Text] [Related]
33. Localized prostate cancer: can we better define who is at risk of unfavourable outcome?
Joniau S; Van Poppel H
BJU Int; 2008 Mar; 101 Suppl 2():5-10. PubMed ID: 18307686
[TBL] [Abstract][Full Text] [Related]
34. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.
Marberger M; Barentsz J; Emberton M; Hugosson J; Loeb S; Klotz L; Koch M; Shariat SF; Vickers A
BJU Int; 2012 Mar; 109 Suppl 2():1-7. PubMed ID: 22257098
[TBL] [Abstract][Full Text] [Related]
35. Pathology of prostate cancer and focal therapy ('male lumpectomy').
Mazzucchelli R; Scarpelli M; Cheng L; Lopez-Beltran A; Galosi AB; Kirkali Z; Montironi R
Anticancer Res; 2009 Dec; 29(12):5155-61. PubMed ID: 20044631
[TBL] [Abstract][Full Text] [Related]
36. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer.
Hara N; Okuizumi M; Koike H; Kawaguchi M; Bilim V
Prostate; 2005 Feb; 62(2):140-7. PubMed ID: 15389803
[TBL] [Abstract][Full Text] [Related]
37. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
Dong F; Kattan MW; Steyerberg EW; Jones JS; Stephenson AJ; Schröder FH; Klein EA
J Urol; 2008 Jul; 180(1):150-4; discussion 154. PubMed ID: 18485398
[TBL] [Abstract][Full Text] [Related]
38. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
[TBL] [Abstract][Full Text] [Related]
39. Phased array magnetic resonance imaging for staging clinically localised prostrate cancer.
Borre M; Lundorf E; Marcussen N; Langkilde NC; Wolf H
Acta Oncol; 2005; 44(6):589-92. PubMed ID: 16294442
[TBL] [Abstract][Full Text] [Related]
40. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
